Snapshot from Jul 01, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Regulatory / ADMA Biologics Channel Stuffing Allegations
Regulatory securities fraud investigation

ADMA Biologics Channel Stuffing Allegations

Analysis based on 123 articles · First reported Apr 01, 2026 · Last updated Jun 29, 2026

Sentiment
-70
Attention
6
Articles
123
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The market is negatively impacted as ADMA Biologics' stock price significantly declined due to allegations of channel stuffing and subsequent securities fraud investigations. This event highlights risks for investors in the biopharmaceutical sector regarding corporate transparency and reporting practices.

biopharmaceutical legal
Event Summary

ADMA Biologics is under investigation by multiple securities law firms, including Bleichmar Fonti & Auld LLP, Rosen Law Firm, and Pomerantz LLP, following a report by Culper Research. The report, published on March 24, 2026, alleges that ADMA Biologics engaged in a 'channel stuffing' scheme in 2025, inducing a distributor to stock excess ASCENIV through rebates and extended payment terms to inflate reported revenue growth. Culper Research claims that without this alleged scheme, ADMA Biologics would have seen a 3% revenue decline instead of the reported 20% growth. This news caused ADMA Biologics' stock to drop by 29% over two trading days, from $13.59 to $9.63 per share. Additionally, Cantor Fitzgerald downgraded ADMA Biologics' stock, further contributing to its decline.

Key Actions
100 Lowey Dannenberg investigating ADMA Biologics
100 Glancy Prongay & Murray filed class action lawsuit ADMA Biologics
98 Bleichmar Fonti & Auld LLP announced investigation ADMA Biologics
95 Culper Research published report ADMA Biologics
95 Pomerantz LLP investigated claims ADMA Biologics
95 Rosen Law Firm announced investigation ADMA Biologics
95 Bronstein, Gewirtz & Grossman, LLC filed class action lawsuit ADMA Biologics
92 Kahn Swick & Foti notified investors of lawsuit ADMA Biologics
90 ADMA Biologics induced distributor stock
90 Faruqi & Faruqi investigating claims against ADMA Biologics
90 Kessler Topaz Meltzer & Check filed lawsuit ADMA Biologics
90 The Schall Law Firm reminded investors of lawsuit ADMA Biologics
90 Robbins Geller Rudman & Dowd LLP announced class action ADMA Biologics
82 ADMA Biologics reported revenue growth
81 ADMA Biologics stock declined
+ 2 more actions View on Dashboard
Entities Involved
stock
ADMA Biologics
ADMA Biologics is the central entity being investigated for alleged securities fraud due to channel stuffing, which caused its stock price to plummet and led to multiple law firms initiating investigations.
Importance 100 Sentiment -80
priv
Culper Research
Culper Research published a report alleging ADMA Biologics engaged in channel stuffing, which triggered the stock drop and subsequent investigations.
Importance 90 Sentiment 70
priv
Bleichmar Fonti & Auld LLP
Bleichmar Fonti & Auld LLP is a leading securities law firm that announced an investigation into ADMA Biologics for potential violations of federal securities laws.
Importance 85 Sentiment 50
priv
Rosen Law Firm
Rosen Law Firm, a global investor rights law firm, announced an investigation into ADMA Biologics for potential securities claims on behalf of shareholders.
Importance 85 Sentiment 40
priv
Lowey Dannenberg
Lowey Dannenberg is investigating ADMA Biologics for potential violations of federal securities laws, focusing on the alleged channel stuffing scheme.
Importance 80 Sentiment 60
priv
Pomerantz LLP
Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics concerning potential securities fraud or other unlawful business practices.
Importance 70 Sentiment 40
priv
Cantor Fitzgerald
Cantor Fitzgerald downgraded ADMA Biologics, citing disappointment with the company's response to the Culper Research report, further contributing to the decline in ADMA Biologics's stock price.
Importance 60 Sentiment 20
per
Andrea Farah
Andrea Farah, a partner at Lowey Dannenberg, is leading the firm's investigation into ADMA Biologics' alleged misconduct.
Importance 60 Sentiment 50
per
Vincent R. Cappucci Jr.
Vincent R. Cappucci Jr., an attorney at Lowey Dannenberg, is involved in the investigation of ADMA Biologics.
Importance 60 Sentiment 50
govactor
United States — United States District Court for the District of New Jersey
The United States — United States District Court for the District of New Jersey is where the class action lawsuit against ADMA Biologics is pending.
Importance 40 Sentiment 0
per
Adam McCall
Adam McCall is a contact person at Bleichmar Fonti & Auld LLP for investors interested in joining the class action against ADMA Biologics.
Importance 30 Sentiment 40
per
Philip Kim
Phillip Kim is a contact person at Rosen Law Firm for investors interested in joining the prospective class action against ADMA Biologics.
Importance 30 Sentiment 40
per
Lawrence Rosen
Lawrence Rosen is a founding partner of Rosen Law Firm, which is investigating ADMA Biologics for securities fraud.
Importance 30 Sentiment 40
index
Nasdaq-100
Nasdaq-100 is the stock exchange where ADMA Biologics is listed.
Importance 5 Sentiment 0
stock
Tesla, Inc.
Tesla, Inc. is mentioned as a company from which Bleichmar Fonti & Auld LLP previously recovered a significant amount in a separate case, demonstrating the law firm's track record.
Importance 0 Sentiment 0
+ 1 more entities View on Dashboard
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.